EUCTR2016-000634-21-IT进行中（未招募）1 期
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn¿s Disease -
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 654
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Have Crohn’s disease or fistulizing Crohn’s disease of at least 3 months’ duration, with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy.
- •- Have active Crohn’s disease, defined as a baseline CDAI score of =220 but =450.
- •Have at least one of the following at screening:
- •a. An abnormal CRP (>0.3 mg/dL [>3.0 mg/L]) OR
- •b. Calprotectin >250 mg/kg.
- •Study 1: Has previously demonstrated inadequate response, loss of response, or intolerance to 1 or more approved biologic therapies OR
- •Study 2: Has failed conventional therapy (currently receiving corticosteroids and/or immunomodulators OR has a history of failure to respond to or tolerate an adequate course of corticosteroids and/or immunomodulators OR is corticosteroid dependent or has had a history of corticosteroid dependency).
- •Part II: Has previously demonstrated inadequate response, loss of response, or intolerance to 1 or more approved biologic therapies or has failed conventional therapy.
- •All 3 Studies:
- •- Adhere to the following requirements for concomitant medication for the treatment of Crohn's disease, which are permitted provided that doses meeting these requirements are stable, or have been discontinued, for at least 3 weeks before baseline (Week 0), unless otherwise specified:
- •a. Oral 5-aminosalicylic acid (5-ASA) compounds.
- •b. Oral corticosteroids at a prednisone-equivalent dose at or below 40 mg/day, or 9 mg/day of budesonide, or 5 mg/day beclomethasone dipropionate.
- •c. Antibiotics being used as a primary treatment of Crohn's disease.
- •d. Conventional immunomodulators (ie, AZA, 6-MP, or MTX): subjects must have been taking them for at least 12 weeks and at a stable dose for at least 4 weeks before baseline.
- •- A subject with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance
- •- A subject who has had extensive colitis for =8 years, or disease limited to the left side of the colon for =12 years, must either have had a colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study agent or a colonoscopy to assess for the presence of malignancy at the screening visit, with no evidence of malignancy.
- •- Have screening laboratory test results within the following parameters:
- •a. Hemoglobin =8.0 g/dL.
- •b. White blood cell count>=3.0 × 103/µL.
- •c. Neutrophils =1.5 × 103/µL.
- •d. Platelets =100 × 103/µL.
- •e. Serum creatinine <1.7 mg/dL.
- •f. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations must be within 2 times the upper limit of the normal range (ULN) range for the laboratory conducting the test.
- •g. Direct (conjugated) bilirubin <1.0 mg/dL.
- •- Are considered eligible according to the following tuberculosis (TB) screening criteria (see details in protocol):
- •a. Have no history of latent or active TB before screening.
- •b. Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- •c. Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB before or simultaneously with the first administration of study agent.
- •d. Within 2 months before the first administration of study agent, either have negative QuantiFER
排除标准
- •1 Has complications of Crohn's disease such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation that might be anticipated to require surgery, could preclude the use of the CDAI, or would possibly confound the ability to assess the effect of treatment with JNJ-64304500 or ustekinumab.
- •2 Currently has or is suspected to have an abscess (see details in protocol).
- •3 Has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months before baseline.
- •4 Has a draining (ie, functioning) stoma or ostomy.
- •5 Has received any of the following prescribed medications or therapies within the specified period:
- •a IV corticosteroids
- •b Other oral immunomodulatory agents (eg, 6-thioguanine [6-TG], cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil, tofacitinib and other Janus kinase [JAK] inhibitors)
- •c Nonbiologic experimental or investigational agents
- •d Nonautologous stem cell therapy (eg, Prochymal), natalizumab, efalizumab, or biologic agents that deplete B or T cells (eg, rituximab, alemtuzumab, or visilizumab)
- •e TNFa-antagonist biologic agents (eg, mAb therapies) or other agents intended to suppress or eliminate TNFa
- •f Vedolizumab
- •g Other immunomodulatory biologic agents
- •h Treatment with apheresis (eg, Adacolumn apheresis)
- •i Initiation of total or partial parenteral nutrition administered through any indwelling catheter or anticipated to require parenteral nutrition administered through an indwelling catheter during enrollment in the study
- •j Initiation of enteral therapy for Crohn's disease (liquid nutritional formula comprising =80% of total caloric intake administered through the gastrointestinal tract). Subjects who are on a stable regimen of enteral feeds may be considered for enrollment if they plan to continue
- •enteral feeds as treatment for Crohn's disease.
- •6 Has a stool culture or other examination positive for an enteric pathogen in the last 4 months unless a repeat examination is negative and there are no signs of ongoing infection with that pathogen.
- •7 Has previously received a biologic agent targeting IL-12 or IL-23
- •8 Has previously received JNJ-64304500 or NNC0142-002
- •9 Has received a Bacille Calmette-Guérin (BCG) vaccination within 12 months or any other live bacterial or live viral vaccination within 12 weeks before baseline
- •10 Has a history of, or ongoing, chronic or recurrent infectious disease
- •11 Has current signs or symptoms of infection. Established nonserious infections (eg, acute upper respiratory tract infection, simple urinary tract infection) need not be considered exclusionary at the discretion of the investigator
- •12 Has a history of serious infection (eg, sepsis, pneumonia, or pyelonephritis)
- •13 Has evidence of a Herpes zoster infection
- •14 Has a history of latent or active granulomatous infection before screening
- •15 Has evidence of current active infection, including TB, or a nodule suspicious for lung malignancy on screening or any other available chest radiograph
- •16 Has or ever has had a nontuberculous mycobacterial infection or serious opportunistic infection
- •17 Has a history of HIV antibody positivity, or tests positive for HIV at screening
- •18 Are seropositive for antibodies to HCV without a history of successful treatment
- •19 Subjects must undergo screening for HBV:
- •a Subjects who test negative for all HBV screening tests (ie, HBsAg-, anti-HBc-, and anti-HBs-) are eligible for this study
- •b Subjects who test positive for surface antigen (HB
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b study for adults hospitalized with Respiratory Syncytial Virus.Respiratory Syncytial Virus InfectionEUCTR2016-001653-40-ESJanssen-Cilag International NV90
进行中（未招募）
1 期
A controlled clinical trial to study RM-131 (relamorelin) in patients with vomiting symptoms and diabetic gastroparesisVomiting symptoms in patient with moderate to severe diabetic gastroparesisMedDRA version: 17.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-005623-27-SERhythm Pharmaceuticals, Inc.395
招募中
2 期
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)CTRI/2023/05/052163Morphic Therapeutic, Inc.
进行中（未招募）
不适用
A study of the safety and drug effects of levodopa inhalation powder (CVT-301) in patients with Parkinson’s diseaseMedDRA version: 14.1Level: LLTClassification code 10034007Term: Parkinson's disease NOSSystem Organ Class: 100000004852Parkinson's DiseaseEUCTR2012-005822-31-GBCivitas Therapeutics, Inc.80
已完成
不适用
To evaluate the efficacy and safety of 14-day multiple oral doses of S-297995 in cancer patients with opioid analgesic-induced constipation in the multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Pharmacokinetics are also assessed.Diseases of the digestive systemKCT0000409Shionogi40